(Q33853657)

29 July 2017

0 references

1 reference

title

Statins for the prevention of contrast-induced nephropathy: a systematic review and meta-analysis (English)

1 reference

contrast-induced nephropathy

29 July 2017

1 reference

1 reference

1 reference

1 reference

Tuo Zhang

1

1 reference

29 July 2017

Ling-Hong Shen

series ordinal

2

1 reference

29 July 2017

Liu-Hua Hu

series ordinal

3

1 reference

29 July 2017

Ben He

series ordinal

4

1 reference

29 July 2017

23 March 2011

1 reference

American Journal of Nephrology

29 July 2017

1 reference

29 July 2017

33

1 reference

29 July 2017

4

1 reference

29 July 2017

344-351

1 reference

Contrast-induced acute kidney injury

29 July 2017

1 reference

Nephrotoxicity of iodixanol versus iopamidol in patients with chronic kidney disease and diabetes mellitus undergoing coronary angiographic procedures

21 January 2018

1 reference

Iodixanol versus low-osmolar contrast media for prevention of contrast induced nephropathy: meta-analysis of randomized, controlled trials

21 January 2018

1 reference

Nephrotoxicity of iso-osmolar iodixanol compared with nonionic low-osmolar contrast media: meta-analysis of randomized controlled trials

21 January 2018

1 reference

The relative renal safety of iodixanol compared with low-osmolar contrast media: a meta-analysis of randomized controlled trials.

21 January 2018

1 reference

Mortality associated with nephropathy after radiographic contrast exposure

21 January 2018

1 reference

Incidence and prognostic importance of acute renal failure after percutaneous coronary intervention

21 January 2018

1 reference

Nephrotoxic effects in high-risk patients undergoing angiography

21 January 2018

1 reference

Multimodality prevention of contrast-induced acute kidney injury

21 January 2018

1 reference

Pleiotropic effects of statins.

21 January 2018

1 reference

The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration

21 January 2018

1 reference

Statins for prevention of contrast-induced nephropathy in patients undergoing non-emergent percutaneous coronary intervention.

21 January 2018

1 reference

Statin therapy reduces contrast-induced nephropathy: an analysis of contemporary percutaneous interventions

21 January 2018

1 reference

Prevention of contrast-induced nephropathy by chronic pravastatin treatment in patients with cardiovascular disease and renal insufficiency

21 January 2018

1 reference

Usefulness of statin pretreatment to prevent contrast-induced nephropathy and to improve long-term outcome in patients undergoing percutaneous coronary intervention.

21 January 2018

1 reference

Efficacy of short-term high-dose atorvastatin for prevention of contrast-induced nephropathy in patients undergoing coronary angiography

21 January 2018

1 reference

Usefulness of atorvastatin (80 mg) in prevention of contrast-induced nephropathy in patients with chronic renal disease

21 January 2018

1 reference

Comparison of usefulness of simvastatin 20 mg versus 80 mg in preventing contrast-induced nephropathy in patients with acute coronary syndrome undergoing percutaneous coronary intervention

21 January 2018

1 reference

Non-lipid-related effects of statins

21 January 2018

1 reference

Inflammation, immunity, and HMG-CoA reductase inhibitors: statins as antiinflammatory agents?

21 January 2018

1 reference

Meta-analysis: effectiveness of drugs for preventing contrast-induced nephropathy

21 January 2018

1 reference

N-acetylcysteine for the prevention of contrast-induced nephropathy. A systematic review and meta-analysis

21 January 2018

1 reference

N-acetylcysteine prophylaxis significantly reduces the risk of radiocontrast-induced nephropathy: comprehensive meta-analysis

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1159/000326269

1 reference

29 July 2017

1 reference